Atreca, Inc. - (BCEL): Price and Financial Metrics


Atreca, Inc. - (BCEL): $1.57

-0.01 (-0.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BCEL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BCEL Stock Price Chart Interactive Chart >

Price chart for BCEL

BCEL Price/Volume Stats

Current price $1.57 52-week high $5.36
Prev. close $1.58 52-week low $0.76
Day low $1.54 Volume 46,700
Day high $1.59 Avg. volume 209,394
50-day MA $1.16 Dividend yield N/A
200-day MA $1.73 Market Cap 61.34M

Atreca, Inc. - (BCEL) Company Bio


Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.


BCEL Latest News Stream


Event/Time News Detail
Loading, please wait...

BCEL Latest Social Stream


Loading social stream, please wait...

View Full BCEL Social Stream

Latest BCEL News From Around the Web

Below are the latest news stories about ATRECA INC that investors may wish to consider to help them evaluate BCEL as an investment opportunity.

We're A Little Worried About Atreca's (NASDAQ:BCEL) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | January 19, 2023

Atreca Appoints Philippe Bishop, MD as Chief Medical Officer

SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Philippe Bishop, MD, as Chief Medical Officer (CMO), effective immediately. “Dr. Bishop is a tremendous addition to the Atreca team at an important time in the clinical development of ATR

Yahoo | January 9, 2023

Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments. "The third quarter was a productiv

Yahoo | November 10, 2022

Atreca to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming conferences: Cowen 6th Annual IO Next SummitNovember 11, 2022Fireside Chat: 2:40-3:00 am EST, November 11, 2022 Stifel Healthcare ConferenceNovember 15-16, 202

Yahoo | November 7, 2022

Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2022 Annual Meeting, being held November 8-12 in Boston, Massachusetts. Details are as follows: Title: Interim Clinical Update of the Phase 1b Trial of ATRC-101 as Monot

Yahoo | October 5, 2022

Read More 'BCEL' Stories Here

BCEL Price Returns

1-mo 98.73%
3-mo 4.67%
6-mo -20.30%
1-year -9.77%
3-year -91.52%
5-year N/A
YTD 96.10%
2022 -73.58%
2021 -81.24%
2020 4.40%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6517 seconds.